UCL  IRIS
Institutional Research Information Service
UCL Logo
Please report any queries concerning the funding data grouped in the sections named "Externally Awarded" or "Internally Disbursed" (shown on the profile page) to your Research Finance Administrator. Your can find your Research Finance Administrator at https://www.ucl.ac.uk/finance/research/rs-contacts.php by entering your department
Please report any queries concerning the student data shown on the profile page to:

Email: portico-services@ucl.ac.uk

Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
Publication Detail
Retrospective analysis of outcome in a cohort of patients with lupus nephritis treated between 1977 and 1999
  • Publication Type:
    Journal article
  • Publication Sub Type:
    Article
  • Authors:
    MacGowan JR, Ellis S, Griffiths M, Isenberg DA
  • Publication date:
    09/2002
  • Pagination:
    981, 987
  • Journal:
    RHEUMATOLOGY (OXFORD)
  • Volume:
    41
  • Issue:
    9
  • Keywords:
    administration & dosage, adult, AGENT, AGENTS, analysis, Biopsy, Class, COHORT, complications, Cyclophosphamide, DEVELOPED, development, difference, disease, drug therapy, END, etiology, Female, health, IM, Immunosuppressive Agent, Immunosuppressive Agents, Injections, Intravenous, INTRAVENOUS, IV, Kidney Failure, Chronic, LA, LONG-TERM, Lupus, Lupus Nephritis, Male, May, Methods, Nephritis, ORGANIZATION, outcome, PARAMETER, PARAMETERS, Patient, patients, physiopathology, Prognosis, prognostic, PROGNOSTIC VALUE, renal, renal disease, Result, RETROSPECTIVE ANALYSIS, Retrospective Studies, Review, Rheumatology, Severity of Illness Index, SLE, Specialist, SYSTEMIC, SYSTEMIC LUPUS ERYTHEMATOSUS, SYSTEMIC-LUPUS-ERYTHEMATOSUS, TERM, therapeutic use, TIME, treatment, unit, WORLD, World Health, World Health Organization
  • Notes:
    UI - 22200055 DA - 20020904 IS - 1462-0324 LA - eng PT - Journal Article RN - 0 (Immunosuppressive Agents) RN - 50-18-0 (Cyclophosphamide) SB - AIM SB - IM
Abstract
OBJECTIVE: To review the development, histological type and outcome of a cohort of patients with lupus nephritis who were managed and followed up by the specialist Bloomsbury Rheumatology Unit between 1977 and 1999. PATIENTS AND METHODS: Seventy-eight of the 280 (28%) patients with systemic lupus erythematosus (SLE) developed nephritis. Occurrence of end stage renal disease (ESRD) according to World Health Organization (WHO) class was analysed, and patients were subdivided according to whether treatment included at least six pulses of intravenous (i.v.) cyclophosphamide (CYC) once a month. RESULTS: For patients with WHO class III nephritis, three out of five treated with i.v. CYC developed ESRD compared with none out of 10 not treated with i.v. CYC (P < 0.02). There was no significant difference between these subgroups in terms of a variety of parameters with good prognostic value, except anti-dsDNA titre at time of biopsy (which was greater in the former). For patients with WHO class IV nephritis, three out of 16 treated with i.v. CYC developed ESRD, compared with five out of 20 not treated with i.v. CYC (no significant difference). CONCLUSION: These data suggest that there may be a subgroup of patients with lupus nephritis (WHO class III) whose long-term outcome is not adversely affected by the omission of i.v. CYC
Publication data is maintained in RPS. Visit https://rps.ucl.ac.uk
 More search options
UCL Researchers
University College London - Gower Street - London - WC1E 6BT Tel:+44 (0)20 7679 2000

© UCL 1999–2011

Search by